Literature DB >> 22427560

Pointwise rates of visual field progression cluster according to retinal nerve fiber layer bundles.

Kouros Nouri-Mahdavi1, Dennis Mock, Hamid Hosseini, Elena Bitrian, Fei Yu, Abdelmonem Afifi, Anne L Coleman, Joseph Caprioli.   

Abstract

PURPOSE: To explore whether pointwise rates of visual field progression group together in patterns consistent with retinal nerve fiber layer (RNFL) bundles.
METHODS: Three hundred eighty-nine eyes of 309 patients from the Advanced Glaucoma Intervention Study with ≥6 years of follow-up and ≥12 reliable visual field exams were selected. Linear and exponential regression models were used to estimate pointwise rates of change over time. Clustering of pointwise rates of progression was investigated with hierarchical cluster analysis using Pearson's correlation coefficients as distance measure and an average linkage scheme for building the hierarchy with cutoff value of r > 0.7.
RESULTS: The average mean deviation (±SD) was -10.9 (±5.4). The average (±SD) follow-up time and number of visual field exams were 8.1 (±1.1) years and 15.7 (±3.0), respectively. Pointwise rates of progression across the visual field grouped into clusters consistent with anatomic patterns of RNFL bundles with both linear (10 clusters) and exponential (six clusters) regression models. One hundred forty-four (37%) eyes progressed according to the two-omitting pointwise linear regression model.
CONCLUSIONS: ointwise rates of change in glaucoma patients cluster into regions consistent with RNFL bundle patterns. This finding validates the clinical significance of such pointwise rates. The correlations among pointwise rates of change can be used for spatial filtering purposes, facilitating detection or prediction of glaucoma progression.

Entities:  

Mesh:

Year:  2012        PMID: 22427560     DOI: 10.1167/iovs.11-9021

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  8 in total

1.  Machine learning classifiers-based prediction of normal-tension glaucoma progression in young myopic patients.

Authors:  Jinho Lee; Young Kook Kim; Jin Wook Jeoung; Ahnul Ha; Yong Woo Kim; Ki Ho Park
Journal:  Jpn J Ophthalmol       Date:  2019-12-17       Impact factor: 2.447

Review 2.  Functional assessment of glaucoma: Uncovering progression.

Authors:  Rongrong Hu; Lyne Racette; Kelly S Chen; Chris A Johnson
Journal:  Surv Ophthalmol       Date:  2020-04-26       Impact factor: 6.048

3.  Prediction of glaucomatous visual field progression: pointwise analysis.

Authors:  Kilhwan Shon; Gadi Wollstein; Joel S Schuman; Kyung Rim Sung
Journal:  Curr Eye Res       Date:  2014-07       Impact factor: 2.424

4.  Mapping glaucoma patients' 30-2 and 10-2 visual fields reveals clusters of test points damaged in the 10-2 grid that are not sampled in the sparse 30-2 grid.

Authors:  Ryo Asaoka
Journal:  PLoS One       Date:  2014-06-20       Impact factor: 3.240

5.  Spatial and Temporal Characteristics of Visual Field Progression in Glaucoma Assessed by Parallel Factor Analysis.

Authors:  Seungmo Kim; Kilhwan Shon; Kyung Rim Sung
Journal:  Korean J Ophthalmol       Date:  2019-06

6.  Cluster Formation for Analyses of Glaucomatous Visual Field Defects in Central 10-2 Visual Field in Normal Tension Glaucoma Eyes.

Authors:  Hirotaka Suzumura; Keiji Yoshikawa; Tairo Kimura; Mami Nanno; Toyoaki Tsumura
Journal:  Clin Ophthalmol       Date:  2022-03-03

7.  Multivariate Longitudinal Modeling of Macular Ganglion Cell Complex: Spatiotemporal Correlations and Patterns of Longitudinal Change.

Authors:  Vahid Mohammadzadeh; Erica Su; Lynn Shi; Anne L Coleman; Simon K Law; Joseph Caprioli; Robert E Weiss; Kouros Nouri-Mahdavi
Journal:  Ophthalmol Sci       Date:  2022-06-16

8.  Enhancement of Visual Field Predictions with Pointwise Exponential Regression (PER) and Pointwise Linear Regression (PLR).

Authors:  Esteban Morales; John Mark S de Leon; Niloufar Abdollahi; Fei Yu; Kouros Nouri-Mahdavi; Joseph Caprioli
Journal:  Transl Vis Sci Technol       Date:  2016-03-14       Impact factor: 3.283

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.